Alloreactive cytotoxic CD4+ responses elicited by cytomegalovirus- infected endothelial cells: Role of MHC class I antigens

Viral Immunology

Volumn 13, Issue 1, 2000, Pages 37-47

  Weinberg, Adriana ^a,b   Zhang, Li ^a   Hayward, Anthony R ^a  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ALLOIMMUNITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; ENDOTHELIUM CELL; GRAFT REJECTION; HUMAN; HUMAN CELL; NATURAL KILLER CELL; NONHUMAN; PATHOPHYSIOLOGY;

ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; DNA VIRUSES;

EID: 0034020380     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2000.13.37     Document Type: Article

References (39)

1. Adams, P.W., H.S. Lee, W.J. Waldman, D.D. Sedmak, C.J. Morgan, J.S. Ward, and C.G. Orosz. 1992. Alloantigenicity of human endothelial cells. Frequency and phenotype of human T helper lymphocytes that can react to allogeneic endothelial cells. J. Immunol. 148:3753.
2. Almeida, G.D., C.D. St. Jeor, and J.L. Ascensao. 1994. Human cytomegalovirus alters interleukin-6 production by endothelial cells. Blood 83:370.
3. Azuma, H., and N.L. Tilney. 1994. Chronic graft rejection. Curr. Opinion Immunol. 6:770.
4. Behar E., N.J. Chao, D.D. Hiraki, S. Krishnaswamy, B.W. Grown, J.L. Zehnder, and F.C. Grumet. 1996. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N. Engl. J. Med. 334:286.
5. Bretscher, P. 1992. The two-signal model of lymphocyte activation twenty-one years later. Immunol. Today 13:74.
6. Bretscher, P., and M. Cohn. 1970. A theory of self-nonself discrimination. Science 169:1042.
7. Briscoe, D.M., L.E. Henault, C. Geehan, S.I. Alexander, and A.H. Lichtman. 1997. Human endothelial cell costimulation of T cell IFN-γ production. J. Immunol. 159:3247.
8. + lymphocytes from CD8-/-mice are sufficient to mediate the rejection of MHC class II or class I disparate skin grafts. J. Immunol. 156:4114.
9. De Otero, J., J. Gavaldà, E. Murio, V. Vargas, I. Calico, L. Llopart, J. Rossello, C. Margaridt, and A. Pahissa. 1998. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin. Infect. Dis. 26:865.
10. Epperson, D.E., and J.S. Pober. 1994. Antigen-presenting function of human endothelial cells. Direct activation of resting CD8 T cells. J. Immunol. 153:5402.
11. Grattan, M.T., C.E. Moreno-Cabral, V.A. Starnes, P.E. Oyer, E.B. Stinson, and N.B. Shumway. 1989. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. J. Am. Med. Assn. 26:3561.
12. Guinan, E.G., B.R. Smith, J.T. Doukas, and R.A. Miller. 1989. Vascular endothelial cells enhance T cell responses by markedly augmenting IL-2 concentrations. Cell, Immunol. 118:166.
13. Hayward A.R., K. Buda, M. Jones, C.J. White, and M. Levin. 1996. Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine. Viral Immunol. 9:241.
14. Hughes, C.C.W., C.O.S. Savage, and J.S. Pober. 1990. The endothelial cell as a regulator of T-cell function. Immunol. Rev. 117:85.
15. Hughs, C.C.W., C.O.S. Savage, and J.S. Pober. 1990. Endothelial cells augment T cell interleukin 2 production by a contact-dependent mechanism involving CD2/LFA-3 interaction. J. Exp. Med. 171:1453.
16. Jones R.J., L.K. Hanson, L. Sun, J.S. Slater, R.M. Stenberg, and A.E. Campbell. 1995. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J. Virol. 69:4830.
17. Karmann, K., J.S. Pober, and C.C.W. Hughes. Endothelial cell-induced resistance to cyclosporin A in human peripheral blood T cells requires contact-dependent interactions involved CD2 but not CD28. J. Immunol. 153:3929.
18. Keenan, R.J., M.E. Lega, J.S. Dummer, I.L. Paradis, J.H. Dauber, H. Rabionwich, S.A. Yousem, R.L. Hardesty, B.P. Giffith, R.J. Duquesnoy, and A. Zeevi. 1991. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 51:433.
19. Kos, F.J., and E.G. Engleman. 1995. Requirement for natural killer cells in the induction of cytotoxic T cells. J. Immunol. 155:578.
20. Ng-Bautista, C.L., and D.D. Sedmak. 1995. Cytomegalovirus infection is associated with absence of alveolar epithelial cell HLA class II antigen expression. J. Infect. Dis. 171:39.
21. O'Grady, J.G., S. Sutherland, F. Harvey, R.Y. Calne, G.J.M. Alexander, P.T. Donaldson, B. Portmann, and R. Williams. 1988. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile duct syndrome after transplantation. Lancet ii:302.
22. + T-cell responses to human allogeneic microvascular endothelium. Circulation Res. 69:1269.
23. Peterson, P.K., Balfour, H.H., Marker S.C., Fryd, D.S., Howard, R.J., and Simmons, R.L. 1980. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine 59:283.
24. Riddell, S.R., and P.D. Greenberg. 1990. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Methods 128:189.
25. Rouleau, M., R. Namikawa, S. Antonenko, N. Carballido-Perrig, and M.G. Roncarolo. 1996. Antigen-specific cytotoxic T cells mediate human fetal pancreas allograft rejection in SCID-hu mice. J. Immunol. 157:5710.
26. Rubin, R.H. 1990. Impact of Cytomegalovirus infection in organ transplant recipients. Rev. Infect. Dis. 12:5754.
27. + T cells. Cell. Immunol. 137:150.
28. + T cells proliferate to HLA-DR+ allogeneic vascular endothelium. Transplantation 56:128.
29. Scholz, M., A. Hamann, R.A. Blaheta, M.K.H. Auth, A. Encke, and B.H. Markus. 1992. Cytomegalovirus- and interferon-related effects on human endothelial cells. Cytomegalovirus infection reduces upregulation of HLA class II antigen expression after treatment with interferon-γ. Hum. Immunol. 35:230.
30. Sedmak D.D., S. Chaiwiriyakul, D.A. Knight and W.J. Waldman. 1995. The role of interferon beta in human cytomegalovirus-mediated inhibition of HLA DR induction on endothelial cells. Arch. Virol. 140:111.
31. Sedmak, D.D., A.M. Guglielmo, D.A. Knight, D.J. Birmingham, E. Hi. Huang, and W.J. Waldman. 1994. Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells. Am. J. Pathol. 144:683.
32. Tuder, R.M., A. Weinberg, N. Panajotopoulos, and J. Kalil. 1994. Cytomegalovirus infection amplifies class I MHC expression on cultured human endothelial cells. J. Heart Lung Transplant 13:129.
33. Udaka, K., S. Marusic-Galesic, and P. Waiden. 1994. CD4 and CD8 α,β and γδ T cells are cytotoxic effector cells of β2-microglobulin-deficient mice against cells having normal MHC class I expression. J. Immunol. 153:2843.
34. van Dorp, W.T., E. Jonges, C.A. Bruggeman, M.R. Daha, L.A. van Es, and F.J. van Der Woude. 1989. Direct induction of MHC class I, but not class II, expression on endothelial cells by Cytomegalovirus infection. Transplantation 48:469.
35. Viola, A., and A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273:104.
36. Von Willebrand, E., E. Pettersson, J. Ahonen, and P. Hayry. 1986. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 42:364.
37. Waldman W.J., D.A. Knight, and E.H. Huang. 1998. An in vitro model of T cell activation by autologous cytomegalovirus (CMV)-infected human adult endothelial cells: contribution of CMV-enhanced endothelial ICAM-1. J. Immunol 160:3143.
38. Weinberg A., L. Zhang, and R.M. Tuder. 1996. NK recognition of cytomegalovirus-infected endothelial cells depends on viral replication and MHC class I expression. Viral Immunol. 9:131.
39. Wu M., S.L. Tang, R.J. Zang, and H. Yu. 1990. Selective killing of tumor cells in vitro by an immunotoxin composed of ricin and monoclonal antibody against la antigen. Int. J. Immunopharmacol. 12:235.